ArticleBritish journal of cancer2012
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
S V Holt et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
54 papers cite it
this papertrialcites it